BITOX/immunomanager DOWNLOAD FLYER
The BSMO has initiated an effort to build a consensus electronic document on immune-related Adverse Events (irAE) that is published on the “ImmunoManager website”. The first objective of this project is to provide comprehensive recommendations on the diagnostic algorithm and treatment for the different types of irAE.
The ImmunoManager is designed to be ready for direct clinical implementation by oncologists, generalists and organ specialists and can be consulted online. In the future the website will provide case based illustrations for every irAE. All ImmunoManager recommendations are put together by the BSMO Immuno Task Force in collaboration with organ specialists based on recent publications and clinical experience.
Following this initiative, the task force has organised BITOX, a biweekly virtual meeting between oncologists and organ specialists to discuss all complex immunotherapy cases. Common subjects are rare adverse events or prescribing immunotherapy to patients with underlying autoimmune diseases or transplants. The goal is to gather knowledge and experience about irAEs in order to obtain consenus about their management. Both professionals wishing to present a case or listen to the discussion are very welcome. Cases are submitted online or via mail.
Dr. Sandrine Aspeslagh, UZ Brussel-VUB, Hopital Erasme-ULB
Prof. Jean-François Baurain, UCL
Prof Oliver Bechter, KUL
Dr. Vibeke Kruse, UGent
Prof. Bart Neyns, UZ Brussel-VUB
Dr. Andrée Rorive, CHU Liège
Prof. Dr. S. Aspeslagh (UZB) (Organiser)
Dr. M. Schreuer (ASZ Aalst)
Prof. Dr. A. Drowart (Bordet)
Dr. M. Brandao (Bordet)
Dr. N. Blockx (ZNA)
Prof. Dr. B. Neyns (UZB)
Prof. Dr. E. Wauters (UZLeuven)
Dr. A. Rutten (GZA)
Prof. Dr. J. Dekervel (UZLeuven)
Prof. Dr. O. Bechter (UZLeuven)
Prof. Dr. E. Seront (UCL)
Dr. M. Languou-Fontsa (Bordet)
Pharm. S. Wuyts (UZB)
Dr. M. Verhaert (UZBrussel/UZLeuven)
Please contact the members of the BSMO Immuno Task Force via below response form in case of any question or any observed irAE that is not covered in the ImmunoManager.
